Visão geral da empresa
A Wearable medical robotics company, Myomo, Inc. is dedicated to the design, development, and production of myoelectric orthotics specifically for individuals suffering from neuromuscular disorders within the United States, Germany, and international markets. The firm operates within the Healthcare sector, focusing on the Medical Devices industry, which implies a specialized market characterized by high regulatory standards and significant investment in research and development for assistive technologies. The company currently maintains a market capitalization of $26.96M and employs a workforce of 194 individuals, generating total annual revenue of $40.93M based on trailing twelve-month figures. These valuation metrics indicate that the company is a small-cap entity with a relatively modest revenue base compared to large-cap peers in the medical device space, suggesting a position where growth potential is closely tied to market penetration rather than established scale dominance.
Saúde financeira
Myomo, Inc. reported a trailing twelve-month revenue of $40.93M, yet the company posted a net income loss of $-15,573,884 and an EBITDA of $-13,542,493 during the same period. The substantial gap between positive revenue of $40.93M and a net loss exceeding $15 million reveals a cost structure where operating expenses, likely driven by R&D and manufacturing overhead, significantly outweigh gross profits. The company generated free cash flow of $-11,058,699, which indicates a current lack of financial flexibility and a reliance on external capital sources to fund ongoing operations and product development. Operating margins stand at -24.4%, while the gross margin is 65.7% and the profit margin is -38.1%, highlighting that while the products carry a healthy gross markup, high fixed costs or sales inefficiencies are eroding profitability at the operating and net levels. On the balance sheet, the company holds $18.39M in cash against $19.38M in debt, resulting in a debt-to-equity ratio of 169.97, which characterizes the financial position as highly leveraged relative to its equity base. The current ratio is 3.30, indicating that the company possesses sufficient short-term assets to cover its short-term liabilities, thereby maintaining adequate liquidity despite the net loss position. Furthermore, the Return on Equity is -86.2% and the Return on Assets is -22.3%, metrics that reveal management has yet to generate positive returns on the capital invested in the business or the assets deployed.
Avaliação de valorização
The trailing twelve-month P/E ratio is N/A due to negative earnings, whereas the forward P/E is listed as -2.67, a figure that suggests the market is pricing in expected future profitability improvements or reflects the current inability to value the stock based on traditional earnings multiples. The price-to-book ratio stands at 2.36, indicating that the market values the company at a premium of roughly 2.36 times its net asset value, which may reflect confidence in its intangible assets, intellectual property, or future growth prospects despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 0.66 and the EV/EBITDA of -2.06 provide different perspectives, suggesting the stock trades at a fraction of its sales revenue and possesses a negative enterprise value multiple relative to earnings. The 52-week trading range spans from a low of $0.60 to a high of $4.99, meaning the stock is currently positioned significantly below its recent peak performance levels. The beta value of 1.16 indicates that the stock price exhibits higher volatility than the broader market, moving approximately 16% more aggressively in response to market fluctuations.
Growth & Income
The company experienced a year-over-year revenue growth rate of -5.9%, while earnings growth is N/A due to the absence of positive net income in the comparable period. Since earnings are negative, there is no growth trajectory for profits to accelerate relative to revenue, implying that the primary financial challenge remains achieving operational profitability rather than scaling revenue. Myomo, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all of its earnings, or rather its losses, to reinvest into growth initiatives and product development rather than distributing income to shareholders. This reinvestment strategy is typical for early-stage medical device companies that prioritize expanding their market share and refining their orthotic technologies over providing immediate income yields. Overall, the growth and income profile is defined by contraction in top-line revenue, a lack of dividend income, and a strategic focus on capital preservation and future profitability within a highly competitive healthcare sector.